These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 24463014)

  • 1. A continuous and direct assay to monitor leucine-rich repeat kinase 2 activity.
    Silva RG; Geoghegan KF; Qiu X; Aulabaugh A
    Anal Biochem; 2014 Apr; 450():63-9. PubMed ID: 24463014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
    Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
    Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
    Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
    J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
    Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
    J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.
    Anand VS; Reichling LJ; Lipinski K; Stochaj W; Duan W; Kelleher K; Pungaliya P; Brown EL; Reinhart PH; Somberg R; Hirst WD; Riddle SM; Braithwaite SP
    FEBS J; 2009 Jan; 276(2):466-78. PubMed ID: 19076219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the autophosphorylation sites of LRRK2.
    Kamikawaji S; Ito G; Iwatsubo T
    Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
    Zhao J; Hermanson SB; Carlson CB; Riddle SM; Vogel KW; Bi K; Nichols RJ
    Biochem Soc Trans; 2012 Oct; 40(5):1158-62. PubMed ID: 22988882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2.
    Gloeckner CJ; Boldt K; von Zweydorf F; Helm S; Wiesent L; Sarioglu H; Ueffing M
    J Proteome Res; 2010 Apr; 9(4):1738-45. PubMed ID: 20108944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
    Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a high-throughput AlphaScreen assay measuring full-length LRRK2(G2019S) kinase activity using moesin protein substrate.
    Pedro L; Padrós J; Beaudet L; Schubert HD; Gillardon F; Dahan S
    Anal Biochem; 2010 Sep; 404(1):45-51. PubMed ID: 20434426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors.
    Liu M; Poulose S; Schuman E; Zaitsev AD; Dobson B; Auerbach K; Seyb K; Cuny GD; Glicksman MA; Stein RL; Yue Z
    Anal Biochem; 2010 Sep; 404(2):186-92. PubMed ID: 20566370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2).
    Lovitt B; Vanderporten EC; Sheng Z; Zhu H; Drummond J; Liu Y
    Biochemistry; 2010 Apr; 49(14):3092-100. PubMed ID: 20205471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease.
    Lee BD; Li X; Dawson TM; Dawson VL
    Methods Mol Biol; 2012; 795():45-54. PubMed ID: 21960214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of a selective chemosensor for leucine-rich repeat kinase 2.
    Szalewski DA; Beck JR; Stains CI
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5648-5651. PubMed ID: 25467152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.
    Gilligan PJ
    Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 autophosphorylation enhances its GTPase activity.
    Liu Z; Mobley JA; DeLucas LJ; Kahn RA; West AB
    FASEB J; 2016 Jan; 30(1):336-47. PubMed ID: 26396237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.
    Ito G; Fujimoto T; Kamikawaji S; Kuwahara T; Iwatsubo T
    PLoS One; 2014; 9(5):e97988. PubMed ID: 24836358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.
    Webber PJ; Smith AD; Sen S; Renfrow MB; Mobley JA; West AB
    J Mol Biol; 2011 Sep; 412(1):94-110. PubMed ID: 21806997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
    Göring S; Taymans JM; Baekelandt V; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.